Ikarian Capital, LLC Arcus Biosciences, Inc. Call Options Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $1.56 Million - $2.05 Million	113,700 New	113,700 $1.74 Million
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $5.32 Million - $7.77 Million	396,000 Added 9900.0%	400,000 $7.64 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $3.45 Million - $4.61 Million	-196,000 Reduced 98.0%	4,000 $71,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $3.39 Million - $4.41 Million	200,000 New	200,000 $4.06 Million
Q2 2022 Aug 12, 2022	SELL	$17.23 - $37.73 $2.18 Million - $4.78 Million	-126,800 Reduced 84.53%	23,200 $588,000
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $4.34 Million - $6.27 Million	150,000 New	150,000 $4.73 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.